

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Evens, Andrew M.

eRA COMMONS USER NAME (credential, e.g., agency login): AEVENS

POSITION TITLE: Associate Director (Clinical Services), Rutgers Cancer Institute of New Jersey; Associate Vice Chancellor, Clinical Innovation and Data Analytics, Rutgers Biomedical Health Sciences, Rutgers Univ.

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.*)

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
Saint Joseph's College, Rensselaer, IN	B.S.	06/1991	Biochemistry
Chicago College of Osteopathic Medicine, Downers Grove, IL	D.O.	06/1996	Medicine
Lutheran General Hospital, Park Ridge, IL	Residency	06/1999	Internal Medicine
Lutheran General Hospital, Park Ridge, IL	Residency	06/2000	Chief Medical Resident
Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center	Fellowship	06/2003	Hematology/Oncology (Chief Fellow)
Northwestern University, Chicago, IL	M.Sc.	12/2003	Clinical Investigation
Rutgers Business School, Newark, NJ	M.B.A.	05/2022	Business

A. Personal Statement

I am a cancer clinician, physician scientist, and healthcare executive who serves as Associate Vice Chancellor for Clinical Innovation & Data Analytics with Rutgers Biomedical and Health Sciences (RBHS) at Rutgers University, Associate Director of Rutgers Cancer Institute of New Jersey (CINJ) for Clinical Services, and System Director of Medical Oncology and Oncology Lead for RWJBarnabas-Rutgers Medical Group for RWJBarnabas Health (RWJBH). I work to deliver high quality, advanced, and integrated cancer care for the State's only NCI-designated Comprehensive Cancer Center and I lead a multitude of transdisciplinary efforts central to the operation and innovation of cancer services at 15 acute care hospitals, and associated oncology practices across the oncology service line throughout the State of New Jersey. Via the Chancellor's office at RBHS, I provide leadership on innovation, data analytics and evidence-based decision-making support systems for the University.

I completed a fellowship in Hematology/Oncology in the Division of Hematology and Oncology at Northwestern University Feinberg School of Medicine (NUFSM) and the Robert H. Lurie Comprehensive Cancer Center (RHLCC) where I remained as a faculty member altogether for 11 years. Additionally, during fellowship (night school), I obtained a Master of Science in Clinical Investigation from NUFSM. At RHLCC, I was the Director of Translational Therapeutics for and Associate Director of the Fellowship program. Prior to being recruited to CINJ in 2018, I was Chief of the Division of Hematology/Oncology at Tufts Medical Center and Director of the Tufts Cancer Center in Boston, MA. Most recently, I completed an executive MBA degree at Rutgers Business School.

My individual *research career* is dedicated to lymphoma and focused on 3 areas: 1) Clinical investigation of novel therapeutic agents in lymphoma, including biomarker discovery; 2) Lymphoma biology with systems biology analyses, and 3) Health outcomes in lymphoma, including epidemiology, prognostication and decision making. My research has been continuously funded by the NIH for the past 17+ years. Over the past 18 years, I've been site principal investigator (PI) for >100 prospective cancer clinical trials, which have included >30 investigator-initiated studies (IISs) (20 as overall PI), >25 Cooperative Group (ECOG), and >45 industry studies (5 as National PI). Nationally, I am a core member of the Hodgkin Lymphoma Working Group for the NIH/NCI Steering Committee, Vice Chair of the Lymphoma Working Group for ECOG/ACRIN. Co-chair of the Big 10 Cancer Research Consortium Lymphoma committee, and a recent or current member of several clinical & scientific committees for the NIH, NCI, Cancer Therapy Evaluation Program (CTEP), and the FDA.

I have a longstanding interest in *administration, education, and mentorship*. In New Jersey, I help to lead integrated cancer care across the health system (300+ cancer providers) throughout New Jersey. I am 1 of 45 (re-) elected members to the North American Lymphoma Research Foundation ([LRF Scientific Advisory Board](#)). Additionally, I am dedicated to educational efforts speaking at >75 regional and national educational forums

over the past 5 years. I co-chaired the 2018 & 2019 National LRF Lymphoma Clinical Research Mentoring Program and I was the National Co-Chair for the North American Educational Forum on Lymphoma in 2017 & 2022 sponsored by the LRF. Over the past 18 years, I have also served as the *primary mentor* for >60 medical students, residents, post-docs, and junior faculty on clinical, laboratory, and translational projects and career development. Notably, 25 of 35 house staff trainees are faculty who remained in academic medicine.

For extramural funding, in addition to the **NCI R01 multi-PI** awarded with Dr. Susan Parsons *Modeling Multi-Source Data in Hodgkin Lymphoma* (1 R01 CA262265; 04/01/2022-03/31/2027), I am involved in several ongoing clinical translational cancer grants that include analysis of lymphoma tissue for discovery of pathogenesis and biomarkers: **ORIEN NOVA Team Science Award** (Cohen, Emory (PI); 06/01/2019 – 05/31/2023); role: co-investigator), entitled *Classification of poor-risk relapsed non-Hodgkin lymphoma subtypes*. I am co-investigator for 2 lymphoma **NIH R01s** entitled: *Social genomic mechanisms of health disparities among Adolescent and Young Adult (AYA) cancer survivors* (R01 CA261752-01 (Zebrack/UMich), 07/01/2021-05/31/2026) and another entitled: *Mechanisms of Lymphomagenesis for Skin-Resident Gamma Delta T Cells*; (R01 CA260064 (Choi/Northwestern), 09/01/2021-08/31/2026).

Collectively, I have a long-standing interest in the clinical prognosis, treatment, and survivorship of **Hodgkin lymphoma (HL)**. This has included clinical prognostication, treatment, and decision modeling and health outcomes. At Rutgers CINJ, I am the co-director of the Cancer Survivorship Center of Excellence, which includes the study and clinical care of late effects and long-term outcomes in HL survivors. Furthermore, I am the founding co-PI for the large international multidisciplinary consortium, [HoLISTIC](#) ([Hodgkin Lymphoma International Study for Individual Care](#)) R01 funded project. The below list contains publications directly related this work.

- a. **Parsons SK**, Kelly MJ, Cohen JT, Castellino SM, Henderson TO, Kelly KM, Keller FG, Henzer TJ, Kumar AK, Johnson P, Meyer RM, Radford J, Raemaekers J, Hodgson DC, **Evens AM**. Early-Stage Hodgkin Lymphoma in the Modern Era: Simulation Modeling to Delineate Long-Term Patient Outcomes. *Br J Haematol*. 2018; 182(2):212-221. [PMC6055753](#)
- b. Rodday AM, Hahn T, Kumar AJ, Lindenauer PK, Friedberg JW, **Evens AM**, **Parsons SK**. First-line treatment in older patients with Hodgkin lymphoma: a Surveillance, Epidemiology, and End Results (SEER)-Medicare population-based study. *Br J Haematol*. 2020; 190(2):222-235. [PMC7368808](#)
- c. Rodday AM, Hahn T, Kumar AJ, Lindenauer PK, Friedberg JW, **Evens AM**, **Parsons SK**. Association of Treatment Intensity With Survival in Older Patients With Hodgkin Lymphoma. *JAMA Netw Open*. 2021; 4(10):e2128373. [PMC8531990](#)
- d. Rodday AM, **Parsons SK**, Upshaw JN, Friedberg JW, Gallamini A, Hawkes E, Hodgson D, Johnson P, Link BK, Mou E, Savage KJ, Zinzani PL, Maurer, **Evens AM**. The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium. *J Clin Oncol*. 2022 Dec 10. Online ahead of print.

B. Positions, Scientific Appointments and Honors

Positions

2018 –	Professor of Medicine, Rutgers Robert Wood Johnson Medical School
2015 – 2017	Chan Soon-Shiong Endowed Scholar in Precision Medicine, Tufts MC, Boston, MA
2013 – 2017	Professor of Medicine, Tufts University School of Medicine
2011 – 2013	Associate Professor of Medicine, University of Massachusetts (UMASS) Medical School
2009 – 2010	Associate Professor of Medicine, Northwestern University Feinberg School of Medicine
2006 – 2009	Assistant Professor of Medicine, Northwestern University Feinberg School of Medicine
2003 –	ABIM Board Certified, Medical Oncology and Hematology
2003 – 2010	Attending Physician/Director (WOC), Hematology/Oncology Clinic, Chicago Lakeside VA
2003 – 2006	Instructor in Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL

Scientific and Administrative Appointments

2021 –	Associate Vice Chancellor, Clinical Innovation and Data Analytics, Rutgers Biomedical Health Sciences (RBHS) at Rutgers University
2021 –	Oncology Lead, for the Combined Medical Group (physician organization) of RWJBH system
2020 –	Vice Chair, ECOG/ACRIN Lymphoma Committee, for NCI/NIH
2019 –	Co-chair, Lymphoma Working Group for the Big 10 Cancer Consortium

2018 – Medical Director, Oncology Service Line, RWJBarnabas Health, New Jersey
 2018 – Director, Lymphoma Program, Rutgers Cancer Institute, New Brunswick, NJ
 2018 – Associate Director (for Clinical Services), Rutgers CINJ, New Brunswick, NJ
 2014 – 2017 Director, Tufts Cancer Center, Boston, MA
 2013 – 2017 Chief, Division of Hematology/Oncology, Department of Medicine, Tufts MC, Boston, MA
 2011 – 2013 Deputy Director for Clinical and Translational Research, UMASS Cancer Center
 2011 – 2013 Medical Director, Clinical Research Office, UMass Memorial Cancer Center of Excellence
 2008 – 2010 Director, Translational Therapeutics, Division of Hematology/Oncology, RHLCCC
 2006 – 2010 Associate Fellowship Director (Division of Hematology/Oncology), Robert H. Lurie Comprehensive Cancer Center (RHLCCC) at Northwestern University

Other Experience and Professional Memberships

2021 – Advisory Board and Executive Committee, Infertility and Pregnancy (ABCIP) for International Network on Cancer, Infertility and Pregnancy (<https://esgo.org/network/incip/>)
 2021 Co-chair, National Cancer Institute (NCI) Special Emphasis Panel, SPORE (P50) Review Panel
 2019 – Co-director, Cancer Survivorship Center of Excellence, Rutgers CINJ, New Brunswick, NJ
 2019 – Co-PI *HoLISTIC* (Hodgkin Lymphoma International Study for Individual Care) consortium
 2019 – Named inaugural Editor-in-Chief, *eJHaem* (a Wiley & British Society of Haematology journal)
 2019 – 2021 Chair, DSMC: Tisagenlecleucel versus SOC in adult patients with relapsed or refractory aggressive B-cell NHL: A randomized, open label, phase III trial; CTL019 BELINDA study
 2019 – International Symposium on Hodgkin Lymphoma (ISHL), German Hodgkin Study Group; Cologne, Germany; Scientific Committee Member
 2018 – 2020 ASH, Self-Assessment Program (SAP) Author: Hodgkin Lymphoma
 2018 and 2019 Co-chair, annual North American Clinical Research Mentoring Program (LCRMP), Lymphoma Research Foundation (LRF)
 2018 – Founding Chair/Director (Rutgers CINJ and RWJBH, New Jersey) of: Cancer Pharmacy & Therapeutics (P&T) committee; Virtual Cancer Tumor Board program; Cardio-Oncology Program; and Oncology Tele-Medicine Program
 2018 – New York & Philadelphia Lymphoma Rounds, Steering Committee (Sponsor: LRF)
 2017 & 2022 Co-Chair, North American Educational Forum on Lymphoma, Lymphoma Research Foundation (LRF)
 2017 – 2019 International DSMC member, Pivotal phase 2 study of tisagenlecleucel (CTL019) CAR T-cell therapy in relapsed/refractory DLBCL (JULIET study)
 2014 – 2019 Editorial Board, *Journal of Clinical Oncology*
 2013 – 2017 ECOG Principal Investigator (Institutional), Tufts Medical Center, Tufts Cancer Center
 2012 – 2019 Associate Editor, *British Journal of Haematology*
 2012 – 2017 Hematology Review Panel (Chair), VA Scientific Merit Review (R01). NIH/NCI (term: November 2012 to October 2017)
 2012 – 2014 Disease expert, American Society of Hematology (ASH) ABIM maintenance in lymphoma
 2011 – Hodgkin Lymphoma Working Group member (NIH/NCI Steering Committee)
 2011 – 2017 Founding Chair, New England Lymphoma Rounds, Steering Committee (Sponsor: LRF)
 2011 – 2013 ECOG Principal Investigator (Institutional), UMASS Medical School, Worcester, MA
 2011 – 2013 Primary (voting) member, Institutional Review Board (IRB), UMASS Medical School
 2010 – 2016 Clinical Trial Design & Development Working Group, Quantitative Imaging Network (QIN)
 2010 – 2016 Primary member, Developmental Therapeutics committee, ECOG
 2008 – 2012 Ad Hoc reviewer, Office of Orphan Products Development grant section, FDA
 2005 – Co-Chair, Annual International Chicago Lymphoma Symposium (ICLS) on the Diagnosis and Management of Lymphoma (www.chicagolymphoma.com)

Honors and Awards

2019 – 2022 Named Top Doctor in Cancer Care, New Jersey (*Castle Connolly* and *New Jersey Magazine*)
 2022 Ted Marousas Award, Rutgers Business School

2019	Elected to Board of Trustees, Leukemia and Lymphoma Society, New Jersey Chapter
2019	Grand Marshall, LRF Annual Walk; New York, New York
2017 and 2018	Named Top Doctor, <i>Boston Magazine</i> and <i>Castle Connolly</i>
2015	Advisory Panel to Vice President Joseph Biden (<i>for Cancer Moonshot</i>), Naval Observatory, Washington, DC
2015	Named Chan Soon-Shiong Endowed Scholar in Precision Medicine at Tufts MC
2014 and 2019	Elected to the North American Scientific Advisory Board (SAB), Lymphoma Research Foundation (LRF); re-elected 2019
2008 – 2009	Teaching Attending of the Year, Division Hematology/Oncology, Northwestern University
2008 – 2009	Annual Excellence in Teaching Award, Department of Medicine, Northwestern University
2005	Compassionate Care Annual Award, Woman's Board, Northwestern Memorial Hospital
2002	Translational Research Award (most outstanding research presentation), ECOG's Young Investigators Clinical Scientist Symposium, National ECOG Meeting, Miami, FL
1996	Intern of the Year, Internal Medicine, Lutheran General, Park Ridge, IL
1994	Sigma Sigma Phi, National Osteopathic Honor Society, Downers Grove, IL
1991	<i>Magna Cum Laude</i> , Biochemistry, Saint Joseph's College, Rensselaer, IN
1989	Bill Bradley Academic All-American, NCAA College Basketball

C. Contribution to Science

1. A component of my research career has involved the design, conduct, and analysis of prospective cancer clinical trials in lymphoma. Over the past 18+ years, I have been PI of >90 prospective cancer clinical trials (most in lymphoma), of which have combined institutional clinical budgets of \$9,000,000+. These clinical studies have included phase I, II, and III investigator-initiated studies and most have incorporated novel and targeted immunotherapy agents. Many have also had embedded translational research components investigating host, drug, and tumor-based correlative studies; and most have been multi-center. Several example publications of investigator-initiated studies (IIS) are below.
 - a. **Evens AM**, Advani RH, Helenowski IB, Fanale M, Smith SM, Jovanovic BD, Bociek GR, Klein AK, Winter JN, Gordon LI, Hamlin PA. Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. *Journal of Clinical Oncology* 2018; 30:3015-3022; PMID: [30179569](#)
 - b. **Evens AM**, Hong F, Habermann TM, Advani RH, Gascoyne RD, Witzig TE, Quon A, Ranheim EA, Ansell SM, Cheema PS, Dy PA, O'Brien TE, Winter JN, Cescon TP, Chang JE, Kahl B. A 3-Arm Randomized Phase II Study of Bendamustine/Rituximab With Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408. *Clinical Cancer Research* 2020; 26:4468-4477. PMID: [32532790](#).
 - c. Pearse WB, Petrich AM, Gordon LI, Karmali R, Winter JN, Ma S, Kaplan JB, Behdad A, Klein A, Jovanovic B, Helenowski I, Smith SM, **Evens AM**, Pro B. A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas. *Leuk Lymphoma*. 2021; 62(14):3493-3500. PMID: [34338127](#)
 - d. Allen PB, Savas H, **Evens AM**, Advani RH, Palmer B, Pro B, Karmali R, Mou E, Bearden J, Dillehay G, Bayer RA, Eisner RM, Chmiel JS, O'Shea K, Gordon LI, Winter JN. Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma. *Blood*. 2021; 137:1318-1326. PMID: [32992341](#)
2. I have also had the opportunity to coordinate and lead several large multicenter "real world" analyses, each involving multiple institutions (>20-30 sites per project) including PIs throughout North America and Internationally as well as studies that have leveraged regional and national healthcare utilization data. These projects have typically examined less common lymphoma subtypes and challenging clinical scenarios (i.e., ones difficult to study in prospective studies). The majority have been published in high impact journals and served as preliminary data for clinical studies or translational correlative studies.
 - a. **Evens AM**, Danilov AV, Jagadeesh D, Sperling AL, Kim SH, Vaca RA, Wei C, Rector D, Sundaram S, Reddy N, Lin Y, Farooq U, D'Angelo C, Bond D, Berg S, Churnetski MC, Godara A, Khan N, Choi

YK, Sarraf Yazdy M, Rabinovich E, Varma G, Karmali R, Mian A, Savani M, Burkart M, Martin P, Ren A, Chauhan A, Diefenbach CS, Straker-Edwards A, Klein A, Blum K, Boughan K, Smith SE, Haverkos BM, Orellana-Noia VM, Kenkre V, Zayac AS, Ramdial J, Maliske S, Epperla N, Venugopal P, Feldman T, Smith SD, Stadnik A, David KA, Naik S, Lossos IS, Lunning M, Caimi PF, Kamdar M, Palmisiano N, Bachanova V, Portell CA, Phillips T, Olszewski AJ, Alderuccio JP. Burkitt Lymphoma in the Modern Era: Real World Outcomes and Prognostication Across 30 US Cancer Centers. *Blood*. 2021; 137:374-386. PMID: [32663292](#)

- b. Kumar AJ, Nelson J, Rodday AM, **Evens AM**, Friedberg JW, Wildes TM, Parsons SK. Development and validation of a prediction model for 1-year mortality among older adults with Hodgkin Lymphoma who receive dose-intense chemotherapy. *J Geriatr Oncol*. 2021; 12(8):1233-1239. [PMC8557127](#)
- c. Orellana-Noia VM, Isaac K, Malecek MK, Bartlett NL, Voorhees TJ, Grover NS, Hwang SR, Bennani NN, Hu R, Hill BT, Mou E, Advani R, Carter J, David KA, Ballard HJ, Svoboda J, Churnetski MC, Magarelli G, Feldman T, Cohen JB, **Evens AM**, Portell C. Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma. *Blood Advances*. 2021; 5(18):3623-3632. [PMC8945583](#)
- d. Olszewski AJ, Jakobsen LH, Collins GP, Cwynarski K, Bachanova V, Blum KA, Boughan KM, Bower M, Dalla Pria A, Danilov A, David KA, Diefenbach C, Ellin F, Epperla N, Farooq U, Feldman TA, Gerrie AS, Jagadeesh D, Kamdar M, Karmali R, Kassam S, Kenkre VP, Khan N, Kim SH, Klein AK, Lossos IS, Lunning MA, Martin P, Martinez-Calle N, Montoto S, Naik S, Palmisiano N, Peace D, Phillips EH, Phillips TJ, Portell CA, Reddy N, Santarsieri A, Sarraf Yazdy M, Smeland KB, Smith SE, Smith SD, Sundaram S, Zayac AS, Zhang XY, Zhu C, Cheah CY, El-Galaly TC, **Evens AM**. Burkitt Lymphoma International Prognostic Index. *J Clin Oncol*. 2021; 39:1129-1138. PMID: [33502927](#)

3. An additional component of my research has involved translational laboratory investigations that has focused on lymphomagenesis, predictive biomarkers of cancer therapeutics, and mechanisms of resistance. The laboratory is focused on the study of lymphoma biology and signaling pathways critical for cell death, including biomarker discovery (vis-à-vis cell and tumor tissue analyses). These studies have involved a “systems biology” approach with translational transcriptomics. Most of these collaborative ‘team science’, translational lymphoma translational studies are shown below.

- a. Ravi D, Sarkar S, Purvey S, Passero F, Beheshti A, Chen Y, Mokhtar M, David K, Konry T, **Evens AM**. Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma. *Leukemia*. 2020; 34:1291-1304. PMID: [31772298](#)
- b. Ravi D, Beheshti A, Abermil N, Lansigan F, Kinlaw W, Matthan NR, Mokhtar M, Passero FC Jr, Puliti P, David KA, Dolnikowski GG, Su X, Chen Y, Bijan M, Varshney RR, Kim B, Dave SS, Rudolph MC, **Evens AM**. Oncogenic Integration of Nucleotide Metabolism *via* Fatty Acid Synthase in Non-Hodgkin Lymphoma. *Front Oncol*. 2021; 26:11:725137. [PMC8576537](#)
- c. Bhatt R, Ravi D, **Evens AM**, Parekkadan B. Scaffold-mediated switching of lymphoma metabolism in culture. *Cancer Metab*. 2022; 10:15. [PMC9559005](#)
- d. Ravi D, Beheshti A, Burgess K, Kritharis A, Chen Y, **Evens AM**, Parekkadan B. An Analysis of Transcriptomic Burden Identifies Biological Progression Roadmaps for Hematological Malignancies and Solid Tumors. *Biomedicines*. 2022; 10:2720. [PMC9687799](#)

Complete List of Published Work in MyBibliography:

<https://www.ncbi.nlm.nih.gov/myncbi/andrew.evens.1/bibliography/public/>